Ozurdex completely located inside a crystallized lens - Results of 14 months
Purpose: To report the therapeutic efficacy and results of an accidentally injected intralenticular sustained-release dexamethasone implant (Ozurdex) in a patient with macular edema secondary to central retinal vein occlusion at 14 months after injection. Observations: We present a 70-year-old femal...
Main Authors: | Burhan Baskan, Ayşe Cıcek, Ahmet Gulhan, Medine Gundogan, Sertan Goktas |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-12-01
|
Series: | American Journal of Ophthalmology Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993616300640 |
Similar Items
-
Immortal Ozurdex: A 10-month follow-up of an intralenticular implant
by: B Poornachandra, et al.
Published: (2017-01-01) -
Intralenticular Ozurdex® – One Year Later
by: Kathleen A. Regan, et al.
Published: (2017-12-01) -
Intralenticular Sustained-Release Dexamethasone Implant: Is It Still Effective on Macular Edema
by: Mehmet Ali Sekeroglu, et al.
Published: (2016-02-01) -
Comparison between Ozurdex and intravitreal anti-vascular endothelial growth factor treatment for retinal vein occlusion–related macular edema: A systematic review and meta-analysis of randomized controlled trials
by: Qiuming Hu, et al.
Published: (2019-01-01) -
Combined dexamethasone intravitreal implant (Ozurdex) and macular grid laser versus combined intravitreal bevacizumab and macular grid laser in branch retinal vein occlusion with macular edema
by: Abdelrahman G Salman
Published: (2015-01-01)